BioSpace News Archive

- >50% of Patients Achieve Undetectable or BLOQ HDV RNA at Week 24 - Median Decline of HDV RNA: -3.4 Log at Week 24 - 95% of Patients Achieve >2 Log Decline in HDV RNA at Week 24

Aquilion Precision the Latest System in CT Portfolio with Access to Advanced Intelligent Clear-IQ Engine (AiCE)

Attendees gained valuable insight into how to thrive in the changing oncology landscape

Offers exceptional ease-of-use as the lightest option in ResMed’s Minimalist mask category

iSchemaView, the worldwide leader in advanced imaging for stroke, today launched the newest addition to the RAPID platform, RAPID ICH1 at the 2019 Congress of Neurological Surgeons (CNS) Annual Meeting.

27th European Society of Gene and Cell Therapy (ESGCT) Congress, to be held October 22-25, 2019 in Barcelona, Spain.

Indianapolis-based medical device maker NICO Corporation continues its track record of innovation that is revolutionizing neurosurgery by introducing today at the Congress of Neurological Surgeons (CNS) its newest FDA-cleared product, the NICO Myriad NOVUS™

Capricor Therapeutics (Nasdaq: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and other rare disorders, announced today that it will host a Key Opinion Leader (KOL) call on the role of CAP-1002 in the of treatment of Duchenne Muscular Dystrophy (DMD) on Thursday, October 24th at 10:30am Eastern Time.

The Medical Device Innovation Consortium announced it has been awarded $2.8 million in funding by the U.S. Food and Drug Administration for the expansion of the Case for Quality and medical device cybersecurity programs.

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to report very positive fundamental news, that the Company has received several new additional United States, European, and other jurisdictional formal patent issuances covering Fexapotide Triflutate and its use for prostate and urinary tract disorders.